Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

about

Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Item

http://www.wikidata.org/entity/Q48535444

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@en

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@nl

type

Item

label

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@en

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@nl

prefLabel

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@en

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@nl

P1476

Chemotherapy-induced immunomod ...... ombination chemoimmunotherapy.

@en

P2093

Hua Zheng

http://www.w3.org/2001/XMLSchema#string

Marjorie G Zauderer

http://www.w3.org/2001/XMLSchema#string

Masha Zeltsman

http://www.w3.org/2001/XMLSchema#string

Prasad S Adusumilli

http://www.w3.org/2001/XMLSchema#string

Raj G Vaghjiani

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

Dose translation from animal to human studies revisited

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

P304

913-927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0052

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Takashi Eguchi

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29338609

http://www.w3.org/2001/XMLSchema#string

P932

5810850

http://www.w3.org/2001/XMLSchema#string